1 active not recruiting, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow 700 mg leronlimab: new trials by email Literature Review of 700 mg leronlimab trials Research Report on 700 mg leronlimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen 350 mg leronlimab, 700 mg leronlimab, 200 mg pembrolizumab - Metastatic Colorectal Cancer (mCRC) | Phase 2 | Active not recruiting | CytoDyn, Inc. | 66 | 2025-06-16 | 2026-09-09 |
| Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC 350 mg leronlimab, 525 mg leronlimab, 700 mg leronlimab - Triple Negative Breast Neoplasms | Phase 1 / Phase 2 | Terminated | CytoDyn, Inc. | 10 | 2019-04-22 | 2025-09-09 |
Colorectal Neoplasms (1) · Triple Negative Breast Neoplasms (1)
CytoDyn, Inc. (2)
United States (2)